drugset / Trial / NCT06783257

Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

NCT06783257

Phase 2 Not yet recruiting 150 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multicenter, Randomized, Double-Blind, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of Vonoprazan Fumarate Injection for the Treatment of Peptic Ulcer Bleeding

Timeline

Start
2025-02
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 8 mg Intravenous
Subject Vonorasan Unknown 20 mg Intravenous